Histoplasmosis Treatment Market Analysis

Type (Acute, Chronic)

Based on type, the acute segment in the histoplasmosis treatment market is anticipated to garner the largest share of 60% during the projected period. The growth of this market can be attributed to the high prevalence and easy transmission of the disease. Acute histoplasmosis is more common, which is estimated to boost the segment growth. Acute histoplasmosis is more common than chronic histoplasmosis and it is estimated that 80% of cases are acute.  Furthermore, acute histoplasmosis can be easily transmitted via the inhalation of spores from infected bats or bird droppings. This ease of transmission contributes to the high incidence of this disease. Therefore, it is predicted to drive the segment growth which further might boost the market in the projected time period.

Drug Type (Ketoconazole, Amphotericin B, Itraconazole)

In terms of drug type, the amphotericin B segment is predicted to dominate the global histoplasmosis treatment market by the end of 2036. This increase can be explained by the higher use of amphotericin B for histoplasmosis treatment. The drug is recommended for pregnant women with histoplasmosis demanding immediate treatment. It is also used to treat acute progressive disseminated histoplasmosis as maintenance therapy, which in turn drives up the growth of this segment.

Our in-depth analysis of the global market includes the following segments: